Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 82

1.

Trabectedin triggers direct and NK-mediated cytotoxicity in multiple myeloma.

Cucè M, Gallo Cantafio ME, Siciliano MA, Riillo C, Caracciolo D, Scionti F, Staropoli N, Zuccalà V, Maltese L, Di Vito A, Grillone K, Barbieri V, Arbitrio M, Di Martino MT, Rossi M, Amodio N, Tagliaferri P, Tassone P, Botta C.

J Hematol Oncol. 2019 Mar 21;12(1):32. doi: 10.1186/s13045-019-0714-9.

2.

Replacement of miR-155 Elicits Tumor Suppressive Activity and Antagonizes Bortezomib Resistance in Multiple Myeloma.

Amodio N, Gallo Cantafio ME, Botta C, Agosti V, Federico C, Caracciolo D, Ronchetti D, Rossi M, Driessen C, Neri A, Tagliaferri P, Tassone P.

Cancers (Basel). 2019 Feb 18;11(2). pii: E236. doi: 10.3390/cancers11020236.

3.

Polymorphic Variants in NR1I3 and UGT2B7 Predict Taxane Neurotoxicity and Have Prognostic Relevance in Patients With Breast Cancer: A Case-Control Study.

Arbitrio M, Scionti F, Altomare E, Di Martino MT, Agapito G, Galeano T, Staropoli N, Iuliano E, Grillone F, Fabiani F, Caracciolo D, Cannataro M, Arpino G, Santini D, Tassone P, Tagliaferri P.

Clin Pharmacol Ther. 2019 Aug;106(2):422-431. doi: 10.1002/cpt.1391. Epub 2019 Mar 28.

PMID:
30739312
4.

From Single Level Analysis to Multi-Omics Integrative Approaches: A Powerful Strategy towards the Precision Oncology.

Gallo Cantafio ME, Grillone K, Caracciolo D, Scionti F, Arbitrio M, Barbieri V, Pensabene L, Guzzi PH, Di Martino MT.

High Throughput. 2018 Oct 26;7(4). pii: E33. doi: 10.3390/ht7040033. Review.

5.

The potential role of miRNAs in multiple myeloma therapy.

Caracciolo D, Montesano M, Altomare E, Scionti F, Di Martino MT, Tagliaferri P, Tassone P.

Expert Rev Hematol. 2018 Oct;11(10):793-803. doi: 10.1080/17474086.2018.1517041. Epub 2018 Sep 12. Review.

PMID:
30148649
6.

miR-22 suppresses DNA ligase III addiction in multiple myeloma.

Caracciolo D, Di Martino MT, Amodio N, Morelli E, Montesano M, Botta C, Scionti F, Talarico D, Altomare E, Gallo Cantafio ME, Zuccalà V, Maltese L, Todoerti K, Rossi M, Arbitrio M, Neri A, Tagliaferri P, Tassone P.

Leukemia. 2019 Feb;33(2):487-498. doi: 10.1038/s41375-018-0238-2. Epub 2018 Aug 17.

7.

Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92.

Morelli E, Biamonte L, Federico C, Amodio N, Di Martino MT, Gallo Cantafio ME, Manzoni M, Scionti F, Samur MK, Gullà A, Stamato MA, Pitari MR, Caracciolo D, Sesti S, Frandsen NM, Rossi M, Neri A, Fulciniti M, Munshi NC, Tagliaferri P, Tassone P.

Blood. 2018 Sep 6;132(10):1050-1063. doi: 10.1182/blood-2018-03-836601. Epub 2018 Jul 11.

8.

Survival in HIV-infected patients with lymphoma according to the choice of antiretroviral treatment: an observational multicentre study.

Focà E, Cavaglià G, Rusconi S, Cascavilla A, Cenderello G, Re A, Casari S, van den Bogaart L, Zinzani PL, Caracciolo D, Di Perri G, Bonito A, Lucchini A, Cassola G, Viale P, Calcagno A.

HIV Med. 2018 Jun 4. doi: 10.1111/hiv.12624. [Epub ahead of print]

9.

MALAT1: a druggable long non-coding RNA for targeted anti-cancer approaches.

Amodio N, Raimondi L, Juli G, Stamato MA, Caracciolo D, Tagliaferri P, Tassone P.

J Hematol Oncol. 2018 May 8;11(1):63. doi: 10.1186/s13045-018-0606-4. Review.

10.

Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity.

Amodio N, Stamato MA, Juli G, Morelli E, Fulciniti M, Manzoni M, Taiana E, Agnelli L, Cantafio MEG, Romeo E, Raimondi L, Caracciolo D, Zuccalà V, Rossi M, Neri A, Munshi NC, Tagliaferri P, Tassone P.

Leukemia. 2018 Sep;32(9):1948-1957. doi: 10.1038/s41375-018-0067-3. Epub 2018 Feb 22.

11.

Inhibition of EZH2 triggers the tumor suppressive miR-29b network in multiple myeloma.

Stamato MA, Juli G, Romeo E, Ronchetti D, Arbitrio M, Caracciolo D, Neri A, Tagliaferri P, Tassone P, Amodio N.

Oncotarget. 2017 Nov 20;8(63):106527-106537. doi: 10.18632/oncotarget.22507. eCollection 2017 Dec 5.

12.

MiR-29b antagonizes the pro-inflammatory tumor-promoting activity of multiple myeloma-educated dendritic cells.

Botta C, Cucè M, Pitari MR, Caracciolo D, Gullà A, Morelli E, Riillo C, Biamonte L, Gallo Cantafio ME, Prabhala R, Mignogna C, Di Vito A, Altomare E, Amodio N, Di Martino MT, Correale P, Rossi M, Giordano A, Munshi NC, Tagliaferri P, Tassone P.

Leukemia. 2018 Apr;32(4):1003-1015. doi: 10.1038/leu.2017.336. Epub 2017 Nov 21.

13.

High Incidence of Infections in HIV-positive Patients Treated for Lymphoproliferative Disorders.

Calcagno A, Lucchini A, Caracciolo D, Balbiano R, Bracchi M, Sordella F, Gregori G, Lipani F, Audagnotto S, Chiriotto M, Cavaglia G, Ghisetti V, Di Perri G, Bonora S.

Curr HIV Res. 2017;15(4):258-265. doi: 10.2174/1570162X15666170531085838.

PMID:
28558641
14.

Immunomodulatory Activity of MicroRNAs: Potential Implications for Multiple Myeloma Treatment.

Botta C, Cuce M, Caracciolo D, Fiorillo L, Tagliaferri P, Tassone P.

Curr Cancer Drug Targets. 2017;17(9):819-838. doi: 10.2174/1568009617666170330154756. Review.

PMID:
28359248
15.

Prognostic Role of Pre-Radiation Therapy (18)F-Fluorodeoxyglucose Positron Emission Tomography for Primary Mediastinal B-Cell Lymphomas Treated with R-CHOP or R-CHOP-Like Chemotherapy Plus Radiation.

Filippi AR, Piva C, Levis M, Chiappella A, Caracciolo D, Bellò M, Bisi G, Vitolo U, Ricardi U.

Int J Radiat Oncol Biol Phys. 2016 Jul 15;95(4):1239-43. doi: 10.1016/j.ijrobp.2016.02.057. Epub 2016 Mar 2.

PMID:
27130796
16.

Addition of Rituximab to Involved-Field Radiation Therapy Prolongs Progression-free Survival in Stage I-II Follicular Lymphoma: Results of a Multicenter Study.

Ruella M, Filippi AR, Bruna R, Di Russo A, Magni M, Caracciolo D, Passera R, Matteucci P, Di Nicola M, Corradini P, Parvis G, Gini G, Olivieri A, Ladetto M, Ricardi U, Tarella C, Devizzi L.

Int J Radiat Oncol Biol Phys. 2016 Mar 15;94(4):783-91. doi: 10.1016/j.ijrobp.2015.12.019. Epub 2015 Dec 17.

PMID:
26972651
17.

Mir-221/222 are promising targets for innovative anticancer therapy.

Di Martino MT, Rossi M, Caracciolo D, Gullà A, Tagliaferri P, Tassone P.

Expert Opin Ther Targets. 2016 Sep;20(9):1099-108. doi: 10.1517/14728222.2016.1164693. Epub 2016 Mar 21. Review.

PMID:
26959615
18.

Role of Chemotherapy and Allografting in the Treatment of Acute Lymphoblastic Leukemia.

Giaccone L, Audisio E, Bruno B, Maffini E, D'Ardia S, Caracciolo D, Ferrando F, Butera S, Brunello L, Frairia C, Aydin S, Nicolino B, Festuccia M, Crisà E, Bruna R, Passera R, Boccadoro M, Vitolo U, Busca A, Falda M, Marmont F.

Clin Lymphoma Myeloma Leuk. 2016 Feb;16(2):96-103. doi: 10.1016/j.clml.2015.11.002. Epub 2015 Nov 22.

19.

Co-evolution of hydrological components under climate change scenarios in the Mediterranean area.

Viola F, Francipane A, Caracciolo D, Pumo D, La Loggia G, Noto LV.

Sci Total Environ. 2016 Feb 15;544:515-24. doi: 10.1016/j.scitotenv.2015.12.004. Epub 2015 Dec 8.

PMID:
26674680
20.

Climate change effects on the hydrological regime of small non-perennial river basins.

Pumo D, Caracciolo D, Viola F, Noto LV.

Sci Total Environ. 2016 Jan 15;542(Pt A):76-92. doi: 10.1016/j.scitotenv.2015.10.109. Epub 2015 Oct 27.

PMID:
26519569
21.

Inhibition of miR-21 restores RANKL/OPG ratio in multiple myeloma-derived bone marrow stromal cells and impairs the resorbing activity of mature osteoclasts.

Pitari MR, Rossi M, Amodio N, Botta C, Morelli E, Federico C, Gullà A, Caracciolo D, Di Martino MT, Arbitrio M, Giordano A, Tagliaferri P, Tassone P.

Oncotarget. 2015 Sep 29;6(29):27343-58. doi: 10.18632/oncotarget.4398.

22.

Integrated analysis of microRNAs, transcription factors and target genes expression discloses a specific molecular architecture of hyperdiploid multiple myeloma.

Di Martino MT, Guzzi PH, Caracciolo D, Agnelli L, Neri A, Walker BA, Morgan GJ, Cannataro M, Tassone P, Tagliaferri P.

Oncotarget. 2015 Aug 7;6(22):19132-47.

23.

Rate of primary refractory disease in B and T-cell non-Hodgkin's lymphoma: correlation with long-term survival.

Tarella C, Gueli A, Delaini F, Rossi A, Barbui AM, Gritti G, Boschini C, Caracciolo D, Bruna R, Ruella M, Gottardi D, Passera R, Rambaldi A.

PLoS One. 2014 Sep 25;9(9):e106745. doi: 10.1371/journal.pone.0106745. eCollection 2014.

24.

Is there a critical endometrioma size associated with reduced ovarian responsiveness in assisted reproduction techniques?

Coccia ME, Rizzello F, Barone S, Pinelli S, Rapalini E, Parri C, Caracciolo D, Papageorgiou S, Cima G, Gandini L.

Reprod Biomed Online. 2014 Aug;29(2):259-66. doi: 10.1016/j.rbmo.2014.04.019. Epub 2014 May 15.

PMID:
24947067
25.

Targeting of multiple myeloma-related angiogenesis by miR-199a-5p mimics: in vitro and in vivo anti-tumor activity.

Raimondi L, Amodio N, Di Martino MT, Altomare E, Leotta M, Caracciolo D, Gullà A, Neri A, Taverna S, D'Aquila P, Alessandro R, Giordano A, Tagliaferri P, Tassone P.

Oncotarget. 2014 May 30;5(10):3039-54.

26.

In vitro and in vivo activity of a novel locked nucleic acid (LNA)-inhibitor-miR-221 against multiple myeloma cells.

Di Martino MT, Gullà A, Gallo Cantafio ME, Altomare E, Amodio N, Leone E, Morelli E, Lio SG, Caracciolo D, Rossi M, Frandsen NM, Tagliaferri P, Tassone P.

PLoS One. 2014 Feb 21;9(2):e89659. doi: 10.1371/journal.pone.0089659. eCollection 2014.

27.

The lymphocyte to monocyte ratio improves the IPI-risk definition of diffuse large B-cell lymphoma when rituximab is added to chemotherapy.

Rambaldi A, Boschini C, Gritti G, Delaini F, Oldani E, Rossi A, Barbui AM, Caracciolo D, Ladetto M, Gueli A, De Crescenzo A, Passera R, Devizzi L, Patti C, Gianni AM, Tarella C.

Am J Hematol. 2013 Dec;88(12):1062-7. doi: 10.1002/ajh.23566. Epub 2013 Sep 30.

28.

Radiation therapy in primary mediastinal B-cell lymphoma with positron emission tomography positivity after rituximab chemotherapy.

Filippi AR, Piva C, Giunta F, Bellò M, Chiappella A, Caracciolo D, Zotta M, Douroukas A, Ragona R, Vitolo U, Bisi G, Ricardi U.

Int J Radiat Oncol Biol Phys. 2013 Oct 1;87(2):311-6. doi: 10.1016/j.ijrobp.2013.05.053. Epub 2013 Aug 2.

29.

From target therapy to miRNA therapeutics of human multiple myeloma: theoretical and technological issues in the evolving scenario.

Rossi M, Amodio N, Di Martino MT, Caracciolo D, Tagliaferri P, Tassone P.

Curr Drug Targets. 2013 Sep;14(10):1144-9. Review.

PMID:
23834146
30.

Rituximab-based pre-emptive treatment of molecular relapse in follicular and mantle cell lymphoma.

Ferrero S, Monitillo L, Mantoan B, Barbero D, Genuardi E, Barbiero S, Bernocco E, Caracciolo D, Ruella M, Drandi D, Zanni M, Renna F, Lobetti Bodoni C, Gueli A, Passera R, Musto P, Boccadoro M, Tarella C, Ladetto M.

Ann Hematol. 2013 Nov;92(11):1503-11. doi: 10.1007/s00277-013-1797-y. Epub 2013 Jun 5.

PMID:
23737092
31.

Helicobacter pylori eradication as exclusive treatment for limited-stage gastric diffuse large B-cell lymphoma: results of a multicenter phase 2 trial.

Ferreri AJ, Govi S, Raderer M, Mulè A, Andriani A, Caracciolo D, Devizzi L, Ilariucci F, Luminari S, Viale E, Müllauer L, Dell'Oro S, Arcidiacono PG, Ponzoni M, Patti C.

Blood. 2012 Nov 1;120(18):3858-60. doi: 10.1182/blood-2012-06-438424. No abstract available.

32.

[Children's eye care in Italy through data provided by "Let's see clear" campaign].

Cruciani F, Albanese G, Antonelli B, Mazzeo L, Caracciolo D, Di Pillo S.

Clin Ter. 2011;162(6):e173-85. Italian.

PMID:
22262338
33.

Risk factors for the development of secondary malignancy after high-dose chemotherapy and autograft, with or without rituximab: a 20-year retrospective follow-up study in patients with lymphoma.

Tarella C, Passera R, Magni M, Benedetti F, Rossi A, Gueli A, Patti C, Parvis G, Ciceri F, Gallamini A, Cortelazzo S, Zoli V, Corradini P, Carobbio A, Mulé A, Bosa M, Barbui A, Di Nicola M, Sorio M, Caracciolo D, Gianni AM, Rambaldi A.

J Clin Oncol. 2011 Mar 1;29(7):814-24. doi: 10.1200/JCO.2010.28.9777. Epub 2010 Dec 28.

PMID:
21189387
34.

Comparative assessment of telomere length before and after hematopoietic SCT: role of grafted cells in determining post-transplant telomere status.

Ruella M, Rocci A, Ricca I, Carniti C, Bodoni CL, Ladetto M, Caracciolo D, Boccadoro M, Carlo-Stella C, Corradini P, Tarella C.

Bone Marrow Transplant. 2010 Mar;45(3):505-12. doi: 10.1038/bmt.2009.297. Epub 2009 Oct 19.

PMID:
19838219
35.

Prolonged survival in poor-risk diffuse large B-cell lymphoma following front-line treatment with rituximab-supplemented, early-intensified chemotherapy with multiple autologous hematopoietic stem cell support: a multicenter study by GITIL (Gruppo Italiano Terapie Innovative nei Linfomi).

Tarella C, Zanni M, Di Nicola M, Patti C, Calvi R, Pescarollo A, Zoli V, Fornari A, Novero D, Cabras A, Stella M, Comino A, Remotti D, Ponzoni M, Caracciolo D, Ladetto M, Magni M, Devizzi L, Rosato R, Boccadoro M, Bregni M, Corradini P, Gallamini A, Majolino I, Mirto S, Gianni AM; Gruppo Italiano Terapie Innovative nei Linfomi.

Leukemia. 2007 Aug;21(8):1802-11. Epub 2007 Jun 7.

PMID:
17554382
36.

Long-term lymphoma survivors following high-dose chemotherapy and autograft: evidence of permanent telomere shortening in myeloid cells, associated with marked reduction of bone marrow hematopoietic stem cell reservoir.

Rocci A, Ricca I, Dellacasa C, Longoni P, Compagno M, Francese R, Lobetti Bodoni C, Manzini P, Caracciolo D, Boccadoro M, Ferrero D, Ladetto M, Carlo-Stella C, Tarella C.

Exp Hematol. 2007 Apr;35(4):673-81.

PMID:
17379077
37.

Marked telomere shortening in mobilized peripheral blood progenitor cells (PBPC) following two tightly spaced high-dose chemotherapy courses with G-CSF.

Ricca I, Compagno M, Ladetto M, Rocci A, Dell'Aquila M, Omedè P, De Marco F, D'Antico S, Caracciolo D, Ferrero D, Carlo-Stella C, Tarella C.

Leukemia. 2005 Apr;19(4):644-51.

PMID:
15716989
38.

Intensive chemotherapy in patients with lymphoma. Management of the risk of hyperuricemia.

Tarella C, Bono D, Zanni M, Ricca I, Caracciolo D.

Contrib Nephrol. 2005;147:93-104. doi: 10.1159/000082547. Review.

PMID:
15604609
39.

Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells.

Corradini P, Dodero A, Zallio F, Caracciolo D, Casini M, Bregni M, Narni F, Patriarca F, Boccadoro M, Benedetti F, Rambaldi A, Gianni AM, Tarella C.

J Clin Oncol. 2004 Jun 1;22(11):2172-6.

PMID:
15169805
40.

Patients with high-risk aggressive lymphoma treated with frontline intensive chemotherapy and autografting: evidence of marked differences in outcome between patients with age-adjusted International Prognostic Index scores 2 and 3.

Cuttica A, Zallio F, Ladetto M, Di Nicola M, Caracciolo D, Magni M, Marinone C, Dell'Aquila M, Rosace M, Pileri A, Boccadoro M, Gianni AM, Tarella C.

Cancer. 2003 Sep 1;98(5):983-92.

41.

High-dose ara-C with autologous peripheral blood progenitor cell support induces a marked progenitor cell mobilization: an indication for patients at risk for low mobilization.

Tarella C, Di Nicola M, Caracciolo D, Zallio F, Cuttica A, Omedè P, Bondesan P, Magni M, Matteucci P, Gallamini A, Pileri A, Gianni AM.

Bone Marrow Transplant. 2002 Dec;30(11):725-32.

42.

Feasibility of peripheral blood progenitor cell mobilization and harvest to support chemotherapy intensification in elderly patients with poor prognosis: non-Hodgkin's lymphoma.

Zallio F, Cuttica A, Caracciolo D, Gavarotti P, Bergui L, Giaretta F, Bondesan P, Tassi V, Gallo E, Pileri A, Tarella C.

Ann Hematol. 2002 Aug;81(8):448-53. Epub 2002 Aug 2.

PMID:
12224002
43.

High-dose sequential (HDS) chemotherapy for high-risk non-Hodgkin's lymphoma: long-term analysis and future developments.

Tarella C, Cuttica A, Caracciolo D, Zallio F, Ricca I, Bergui L, Gavarotti P, Marinone C, Pagano M, Rossi G, de Crescenzo A, Salomone A, Ladetto M, Boccadoro M, Pileri A.

Ann Hematol. 2001;80 Suppl 3:B123-6. Review. No abstract available.

PMID:
11757693
44.

Concurrent administration of high-dose chemotherapy and rituximab is a feasible and effective chemo/immunotherapy for patients with high-risk non-Hodgkin's lymphoma.

Ladetto M, Zallio F, Vallet S, Ricca I, Cuttica A, Caracciolo D, Corradini P, Astolfi M, Sametti S, Volpato F, Bondesan P, Vitolo U, Boccadoro M, Pileri A, Gianni AM, Tarella C.

Leukemia. 2001 Dec;15(12):1941-9.

PMID:
11753616
45.

High-dose mitoxantrone + melphalan (MITO/L-PAM) as conditioning regimen supported by peripheral blood progenitor cell (PBPC) autograft in 113 lymphoma patients: high tolerability with reversible cardiotoxicity.

Tarella C, Zallio F, Caracciolo D, Cuttica A, Corradini P, Gavarotti P, Ladetto M, Podio V, Sargiotto A, Rossi G, Gianni AM, Pileri A.

Leukemia. 2001 Feb;15(2):256-63.

PMID:
11236941
46.

Overweight as an adverse prognostic factor for non-Hodgkin's lymphoma patients receiving high-dose chemotherapy and autograft.

Tarella C, Caracciolo D, Gavarotti P, Argentino C, Zallio F, Corradini P, Novero D, Magnani C, Pileri A.

Bone Marrow Transplant. 2000 Dec;26(11):1185-91.

47.

Long-term follow-up of advanced-stage low-grade lymphoma patients treated upfront with high-dose sequential chemotherapy and autograft.

Tarella C, Caracciolo D, Corradini P, Zallio F, Ladetto M, Cuttica A, Rossi G, Novero D, Gavarotti P, Pileri A.

Leukemia. 2000 Apr;14(4):740-7.

PMID:
10764164
48.

Negative immunomagnetic ex vivo purging combined with high-dose chemotherapy with peripheral blood progenitor cell autograft in follicular lymphoma patients: evidence for long-term clinical and molecular remissions.

Tarella C, Corradini P, Astolfi M, Bondesan P, Caracciolo D, Cherasco C, Ladetto M, Giaretta F, Ricca I, Vitolo U, Pileri A, Ferrero D.

Leukemia. 1999 Sep;13(9):1456-62.

PMID:
10482999
49.

Hemopoietic progenitor cell mobilization and harvest following an intensive chemotherapy debulking in indolent lymphoma patients.

Tarella C, Zallio F, Caracciolo D, Cherasco C, Bondesan P, Gavarotti P, Corradini P, Tassi V, Pileri A.

Stem Cells. 1999;17(1):55-61.

50.

Allogeneic transplantation of unmanipulated peripheral blood stem cells in patients with multiple myeloma.

Majolino I, Corradini P, Scimè R, Santoro A, Tarella C, Cavallaro AM, Palumbo A, Indovina A, Caracciolo D, Boccadoro M, Marcenò R, Pileri A.

Bone Marrow Transplant. 1998 Sep;22(5):449-55.

Supplemental Content

Loading ...
Support Center